Vetigenics, founded in 2018, is dedicated to revolutionizing veterinary medicine by developing innovative antibody therapies for cancer and chronic diseases in pets. The company's core mission is to enhance the quality of life for companion animals through advanced, targeted immunotherapies. Vetigenics focuses on creating monoclonal antibodies that specifically target and treat various ailments in pets, with a particular emphasis on oncology and chronic conditions.
Notable affiliated individuals include experts in veterinary medicine and biotechnology, who bring extensive experience to the company. Vetigenics has garnered attention for its pioneering work, including the commencement of a pilot clinical trial for a canine anti-cPD1 monoclonal antibody aimed at treating bladder cancer in dogs. This milestone underscores the company's impact on advancing pet healthcare and its potential to transform treatment paradigms for chronic and life-threatening diseases in companion animals.
